Education
About Us
Working with TipRanks
Follow Us
Wakamoto Pharmaceutical Co., Ltd. (JP:4512)
:4512
Total Valuation
Wakamoto Pharmaceutical Co., Ltd. has a market cap or net worth of ¥10.41B. The enterprise value is ―.
Market Cap¥10.41B
Enterprise Value―
Share Statistics
Wakamoto Pharmaceutical Co., Ltd. has 34,838,326 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding34,838,326
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Wakamoto Pharmaceutical Co., Ltd.’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee19.20M
Profits Per Employee394.18K
Employee Count403
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Wakamoto Pharmaceutical Co., Ltd. is ―. Wakamoto Pharmaceutical Co., Ltd.’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio―
Price to Fair Value―
Price to FCF―
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Wakamoto Pharmaceutical Co., Ltd. had revenue of 7.74B and earned 108.96M in profits. Earnings per share was 3.14.
Revenue7.74B
Gross Profit3.54B
Operating Income-195.51M
Pretax Income158.85M
Net Income108.96M
EBITDA504.84M
Earnings Per Share (EPS)3.14
Cash Flow
In the last 12 months, operating cash flow was 820.56M and capital expenditures 0.00, giving a free cash flow of 820.56M billion.
Operating Cash Flow820.56M
Free Cash Flow820.56M
Free Cash Flow per Share23.55
Dividends & Yields
Wakamoto Pharmaceutical Co., Ltd. pays an annual dividend of ¥3, resulting in a dividend yield of 1%
Dividend Per Share¥3
Dividend Yield1%
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change20.16%
50-Day Moving Average311.48
200-Day Moving Average263.39
Relative Strength Index (RSI)54.70
Average Volume (3m)285.78K
Important Dates
Wakamoto Pharmaceutical Co., Ltd. upcoming earnings date is Aug 1, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 1, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Wakamoto Pharmaceutical Co., Ltd. as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Wakamoto Pharmaceutical Co., Ltd. has paid 49.90M in taxes.
Income Tax49.90M
Effective Tax Rate―
Enterprise Valuation
Wakamoto Pharmaceutical Co., Ltd. EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Wakamoto Pharmaceutical Co., Ltd. has ¥3.56B in cash and marketable securities with ¥100.00M in debt, giving a net cash position of -¥3.46B billion.
Cash & Marketable Securities¥3.56B
Total Debt¥100.00M
Net Cash-¥3.46B
Net Cash Per Share-¥99.33
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Wakamoto Pharmaceutical Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast0.66%
EPS Growth Forecast-40.86%